Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials Post published:December 15, 2020 Post category:Press Release
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms Post published:December 8, 2020 Post category:Press Release
Mydecine Innovations Group Offers Management and Clinical Trials Update Post published:November 17, 2020 Post category:Press Release
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange Post published:October 16, 2020 Post category:Press Release
Mydecine Innovations Group subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities Post published:October 14, 2020 Post category:Press Release
Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin Post published:October 7, 2020 Post category:Press Release
Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today Post published:September 30, 2020 Post category:Press Release
Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration Post published:September 24, 2020 Post category:Press Release
Mindleap Health Implements HIPAA Compliance Standards and Appoints Former Canadian Ministry of Health Telemedicine Expert as Head of Program Management Post published:September 17, 2020 Post category:Press Release
Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets Post published:September 15, 2020 Post category:Press Release